Caplin Point Laboratories Ltd

Caplin Point Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Caplin Point Laboratories Ltd

₹ 1,477 -1.35%
22 Jul - close price
caplinpoint.net BSE: 524742 NSE: CAPLIPOINT
About

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Key Points

Product Portfolio[1]
Presently, the company has a very wide portfolio of pharma products with 4,000+ registered products, 650+ formulations and presence in 36 therapeutic segments. It has minimal reliance for revenues on a single product/ therapeutic segment.

Website BSE NSE
  • Market Cap ₹ 11,210 Cr.
  • Current Price ₹ 1,477
  • High / Low ₹ 1,619 / 839
  • Stock P/E 39.5
  • Book Value ₹ 183
  • Dividend Yield 0.30 %
  • ROCE 28.9 %
  • ROE 22.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 8.07 times its book value
  • The company has delivered a poor sales growth of 3.09% over past five years.
  • Earnings include an other income of Rs.106 Cr.
  • Debtor days have increased from 57.7 to 75.1 days.
  • Working capital days have increased from 124 days to 215 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
123 128 160 128 112 116 137 131 145 174 179 133 139
80 71 89 75 74 70 80 79 80 97 90 70 82
Operating Profit 43 56 71 53 38 46 57 52 65 77 89 63 58
OPM % 35% 44% 45% 42% 34% 40% 42% 39% 45% 44% 50% 48% 41%
7 19 18 9 10 35 22 29 12 27 24 18 36
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 6 6 6 6 7 6 7 6 6 7 7 7 7
Profit before tax 45 69 83 56 42 75 73 74 71 97 107 74 87
Tax % 29% 21% 22% 30% 30% 15% 22% 20% 23% 22% 23% 26% 20%
31 55 65 39 29 63 58 59 54 76 82 55 70
EPS in Rs 4.16 7.21 8.61 5.16 3.83 8.34 7.59 7.80 7.16 10.04 10.81 7.30 9.20
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
123 166 240 231 342 427 537 528 483 528 529 625
101 132 183 169 248 284 348 321 269 308 308 338
Operating Profit 22 34 57 63 94 142 189 207 214 220 220 287
OPM % 18% 20% 24% 27% 27% 33% 35% 39% 44% 42% 42% 46%
2 3 3 3 13 23 35 66 19 56 99 106
Interest 1 1 1 0 0 1 0 0 0 0 0 0
Depreciation 1 3 8 7 13 19 21 20 22 26 26 27
Profit before tax 22 33 51 58 93 146 203 253 210 250 293 366
Tax % 34% 23% 19% 22% 24% 30% 27% 22% 26% 25% 20% 22%
14 26 41 45 70 102 148 198 156 188 234 284
EPS in Rs 1.89 3.39 5.42 6.00 9.30 13.53 19.59 26.13 20.65 24.79 30.86 37.36
Dividend Payout % 26% 24% 18% 20% 16% 15% 11% 10% 15% 16% 15% 7%
Compounded Sales Growth
10 Years: 18%
5 Years: 3%
3 Years: 9%
TTM: 18%
Compounded Profit Growth
10 Years: 35%
5 Years: 14%
3 Years: 23%
TTM: 22%
Stock Price CAGR
10 Years: 37%
5 Years: 31%
3 Years: 23%
1 Year: 73%
Return on Equity
10 Years: 27%
5 Years: 24%
3 Years: 22%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 15 15 15 15 15 15 15 15 15 15 15 15
Reserves 29 47 79 113 185 280 417 585 744 915 1,125 1,375
5 3 2 2 1 1 1 2 1 1 1 1
79 109 128 132 116 115 107 89 101 123 162 131
Total Liabilities 128 174 223 263 317 411 539 691 861 1,054 1,303 1,522
31 101 111 143 152 169 138 167 183 162 157 166
CWIP 51 25 31 0 3 15 9 4 1 3 43 28
Investments 1 1 1 1 19 48 168 196 149 265 434 584
44 48 80 118 143 178 225 325 528 624 670 745
Total Assets 128 174 223 263 317 411 539 691 861 1,054 1,303 1,522

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
33 60 50 44 55 23 107 87 295 231 157 112
-45 -44 -24 -6 -37 -60 -76 -41 -4 -276 -86 -112
-2 -6 -9 -14 -7 -12 -15 -33 -3 -23 -30 -34
Net Cash Flow -14 10 17 24 12 -49 16 13 287 -68 41 -35

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 2 0 0 11 3 74 85 151 74 37 61 75
Inventory Days 40 29 36 56 50 58 36 34 47 76 95 153
Days Payable 99 100 108 161 149 148 92 79 131 116 150 140
Cash Conversion Cycle -58 -72 -72 -94 -95 -16 30 107 -10 -2 6 89
Working Capital Days -164 -175 -125 -112 -44 44 62 137 61 96 60 215
ROCE % 50% 60% 64% 60% 56% 58% 55% 48% 30% 29% 28% 29%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
69.03% 68.91% 68.89% 68.88% 68.88% 68.80% 70.66% 70.63% 70.62% 70.62% 70.62% 70.56%
1.76% 2.11% 2.07% 2.03% 2.15% 2.24% 2.36% 2.68% 3.09% 2.84% 3.33% 3.38%
1.19% 1.22% 1.25% 1.12% 1.12% 1.12% 0.64% 0.27% 0.21% 0.43% 1.08% 1.49%
28.02% 27.76% 27.78% 27.97% 27.85% 27.84% 26.33% 26.44% 26.08% 26.11% 24.95% 24.59%
No. of Shareholders 83,46285,57783,82984,86884,53882,68782,14678,95678,06879,43881,40980,411

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls